Goldman Sachs Maintains Neutral on Dentsply Sirona, Lowers Price Target to $41
Goldman Sachs analyst Nathan Rich maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $42 to $41.
UBS Upgrades Dentsply Sirona to Buy, Lowers Price Target to $47
UBS analyst Kevin Caliendo upgrades Dentsply Sirona (NASDAQ:XRAY) from Neutral to Buy and lowers the price target from $58 to $47.
Why Did Moderna CFO Exit Just A Day After Taking Charge
Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The…
What 10 Analyst Ratings Have To Say About Dentsply Sirona
Analysts have provided the following ratings for Dentsply Sirona (NASDAQ:XRAY) within the last quarter:
Dentsply Sirona’s Q1 Earnings Miss Street Expectations, Cuts FY22 Guidance
Dentsply Sirona Inc’s (NASDAQ:XRAY) Q1 FY22 sales decreased 6.1% Y/Y to $965 million, missing the consensus of $988.43 billion. Adjusted…